Global Disseminated Intravascular Coagulation (DIC) Market Trends: Regional Breakdowns and Strategic Insights
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
How Has The Disseminated Intravascular Coagulation (DIC) Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market for disseminated intravascular coagulation (DIC) has seen robust expansion in the past few years. It’s projected that the market value will progress from $0.46 billion in 2024 to $0.49 billion in 2025, rising at a compound annual growth rate (CAGR) of 5.3%. The growth experienced during the historical period is due to factors such as the rising prevalence of sepsis, a surge in trauma cases, increasing instances of cancer, greater expenditure on healthcare, improved knowledge among healthcare professionals, and the growing utilization of targeted therapies.
The market for disseminated intravascular coagulation (DIC) is set to experience significant growth in the coming years, with the industry projected to attain a value of $0.59 billion by 2029, registering a compound annual growth rate (CAGR) of 5.0%. Factors fueling the predicted growth during the forecast period include increased uptake of targeted treatments, heightened emphasis on preliminary detection of the disease, boosted investment in healthcare facilities, enlargement of clinical studies focusing on coagulopathy remedies, and enhanced knowledge of uncommon blood disorders. The forecast period is likely to see several trends such as advanced diagnostic tests, implementation of unique anticoagulant treatments, the application of personalized medicine methods, use of AI in diagnostic procedures, upgraded patient-monitoring equipment, and development of specialized treatments.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21172&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Disseminated Intravascular Coagulation (DIC) Market?
The anticipated rise in cancer cases is predicted to propel the development of the disseminated intravascular coagulation (DIC) market. Characterized by the unchecked proliferation and dissemination of abnormal cells, cancer wreaks havoc on normal tissue. The surge in cancer instances is attributed to an array of causes including an aging demographic, changes in lifestyle, environmental hazards, infections and a genetic susceptibility. The link between cancer and DIC stems from tumors instigating an overdrive of the coagulation cascade through the release of procoagulant substances, resulting in extensive clotting and bleeding events. Data recorded by the National Cancer Institute, an American government organization, in May 2024 highlighted approximately 20 million fresh cancer instances and 9.7 million cancer-associated fatalities globally in 2022. These figures are set to escalate to 29.9 million fresh instances and 15.3 million annual fatalities by 2040. Consequently, the augmenting prevalence of cancer is instrumental in bolstering the growth of the disseminated intravascular coagulation (DIC) market.
Which Key Market Segments Comprise the Disseminated Intravascular Coagulation (DIC) Market and Drive Its Revenue Growth?
The disseminated intravascular coagulation (DIC) market covered in this report is segmented –
1) By Treatment: Medicines, Transfusions, Surgery, Other Treatments
2) By Diagnosis: Complete Blood Count With Blood Smear Exam, Partial Thromboplastin Time (PTT), Fibrinogen Blood Test, D-dimer, Other Diagnoses
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Medicines: Anticoagulants, Antiplatelet Drugs, Fibrinolytics, Procoagulants, Antithrombin Therapy
2) By Transfusions: Platelet Transfusion, Fresh Frozen Plasma (FFP), Cryoprecipitate Transfusion, Red Blood Cell Transfusion
3) By Surgery: Surgical Removal Of Thrombus, Organ Surgery
4) By Other Treatments: Plasma Exchange, Supportive Care, Steroid Therapy
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21172&type=smp
Which Areas Are Leading Regions in the Disseminated Intravascular Coagulation (DIC) Market Expansion Across the Globe?
North America was the largest region in the disseminated intravascular coagulation (DIC) market in 2024. The regions covered in the disseminated intravascular coagulation (DIC) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theDisseminated Intravascular Coagulation (DIC) Market Direction?
Leading firms in the disseminated intravascular coagulation (DIC) marketplace are concentrating on upgrading coagulation diagnostic technologies, such as cutting-edge blood clotting tests, to optimize the precision, speed, and simplicity of DIC diagnostics. This facilitates swifter interventions and better patient outcomes. Advanced blood clotting examinations refer to innovative diagnostic approaches that can evaluate blood coagulation more accurately and efficiently than conventional tests. For example, LumiraDx Limited, a healthcare company based in the UK, broadened its cardiovascular examination range in June 2022 with CE Mark approvals for its updated D-Dimer and NT-proBNP tests. These developments have amplified the capacity of the LumiraDx Platform to assist medical professionals in diagnosing heart failure and preventing venous thromboembolism at the care point. The goal of these innovations is to enhance the early detection and treatment of cardiovascular and thrombotic disorders, including disseminated intravascular coagulation (DIC).
View the full report here:
How Is the Disseminated Intravascular Coagulation (DIC) Market Conceptually Defined?
Disseminated intravascular coagulation (DIC) is a complex, life-threatening condition characterized by excessive blood clotting followed by severe bleeding due to the depletion of clotting factors and platelets. It is triggered by underlying conditions such as sepsis, trauma, malignancies, and obstetric complications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21172
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
